Immuron (Immuron) Accounts Payable & Accrued Expense : $1.11 Mil (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Immuron Accounts Payable & Accrued Expense?

Immuron's quarterly accounts payable & accrued expense increased from Dec. 2022 ($0.21 Mil) to Jun. 2023 ($0.80 Mil) and increased from Jun. 2023 ($0.80 Mil) to Dec. 2023 ($1.11 Mil).

Immuron's annual accounts payable & accrued expense increased from Jun. 2021 ($0.58 Mil) to Jun. 2022 ($0.82 Mil) but then declined from Jun. 2022 ($0.82 Mil) to Jun. 2023 ($0.80 Mil).

Immuron Accounts Payable & Accrued Expense Historical Data

The historical data trend for Immuron's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immuron Accounts Payable & Accrued Expense Chart

Immuron Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

0.76

0.27

0.58

0.82

0.80

Immuron Semi-Annual Data
	Jun15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial												0.50	0.82	0.21	0.80	1.11

Immuron Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Immuron (Immuron) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuron Ltd (NAS:IMRN) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

ANWA:Germany IMC:Australia

Address

Chapman Street, Unit 10, 25-37, Blackburn North, Melbourne, VIC, AUS, 3130

Website

https://www.immuron.com.au

Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.